March 16, 2016 / 10:48 PM / a year ago

BRIEF-Helix Biopharma Q2 loss per share C$0.03

1 Min Read

March 16 (Reuters) - Helix Biopharma Corp :

* Helix Biopharma Corp. announces second quarter fiscal 2016 results

* Cash reserves as at January 31, 2016 insufficient to see current research and development initiatives through to completion

* Management considers securing additional funds, expected to be through issuance of equity securities of company

* Q2 loss per share C$0.03

* Cash reserves as at Jan 31, 2016, are insufficient to meet anticipated cash needs for working capital and capital expenditures through next 12 months Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below